Institute backs development of drug to protect brain from radiotherapy

The National Cancer Institute gave Chrysalis BioTherapeutics $1.5 million for the continued development of Chrysalin, a regenerative peptide that could lessen radiotherapy-induced brain tissue damage. In clinical trials involving skin healing and bone repair, adverse events were not reported, said Darrell H. Carney, founder and CEO of Chrysalis.

View Full Article in:

American City Business Journals · Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI